FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1861-1872 May 5, 2005 Number 18 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial.

Methods In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4.5 years. The primary end point was the time to recurrence of atrial fibrillation beginning on day 28, determined by means of weekly transtelephonic monitoring.

Results Spontaneous conversion occurred in 27.1 percent of the amiodarone group, 24.2 percent of the sotalol group, and 0.8 percent of the placebo group, and direct-current cardioversion failed in 27.7 percent, 26.5 percent, and 32.1 percent, respectively. The median times to a recurrence of atrial f ibrillation were 487 days in the amiodarone group, 74 days in the sotalol group, and 6 days in the placebo group according to intention to treat and 809, 209, and 13 days, respectively, according to treatment received. Amiodarone was superior to sotalol (P<0.001) and to placebo (P<0.001), and sotalol was superior to placebo (P<0.001). In patients with ischemic heart disease, the median time to a recurrence of atrial fibrillation was 569 days with amiodarone therapy and 428 days with sotalol therapy (P=0.53). Restoration and maintenance of sinus rhythm significantly improved the quality of life and exercise capacity. There were no significant differences in major adverse events among the three groups.

Conclusions Amiodarone and sotalol are equally efficacious in converting atrial fibrillation to sinus rhythm. Amiodarone is superior for maintaining sinus rhythm, but both drugs have similar efficacy in patients with ischemic heart disease. Sustained sinus rhythm is associated with an improved quality of life and improved exercise performance.

Source Information

From the Department of Veterans Affairs Medical Center, West Los Angeles, Calif. (B.N.S., B.L.); the Department of Veterans Affairs Medical Center, Washington, D.C. (S.N.S., R.D.F.); the Department of Veterans Affairs Hospital, Hines, Ill. (D.J.R., X.C.T.); the Department of Veterans Affairs Medical Center, Albuquerque, N.M. (C.L.H., D.W.R.); the Department of Veterans Affairs Medical Center, Providence, R.I. (S.C.S.); Walter Reed Army Medical Center, Washington, D.C. (J.E.A.); the Department of Veterans Affairs Medical Center, Loma Linda, Calif. (A.K.J.); the Department of Veterans Affairs Medical Center, Kansas City, Mo. (H.D.L.); and Hahnemann University and the Department of Veterans Affairs Medical Center Philadelphia — both in Philadelphia (M.D.E.).

Address reprint requests to Dr. Singh at the Veterans Affairs Medical Center of West Los Angeles, 11301 Wilshire Blvd., Los Angeles, CA 90073, or at bsingh{at}ucla.edu.

Full Text of this Article

Related Letters:

Amiodarone versus Sotalol for Atrial Fibrillation
Rubinstein J., Zimetbaum P. J., Josephson M. E., Schlegel A., Desai K. R., Singh B. N., Singh S. N., Reda D.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:627-630, Aug 11, 2005. Correspondence

This article has been cited by other articles:

• Forleo, G. B., Tondo, C. (2009). Atrial fibrillation: cure or treat?. Ther Adv Cardiovasc Dis 3: 187-196 [Abstract]  
• Kim, M. H, Klingman, D., Lin, J., Pathak, P., Battleman, D. S (2009). Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation. The Annals of Pharmacotherapy 43: 840-848 [Abstract] [Full Text]  
• Zimetbaum, P. J. (2009). Dronedarone for Atrial Fibrillation -- An Odyssey. NEJM 360: 1811-1813 [Full Text]  
• Arya, A., Silberbauer, J., Teichman, S. L., Milner, P., Sulke, N., Camm, A. J. (2009). A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 11: 458-464 [Abstract] [Full Text]  
• Verma, A. (2009). Alternatives to amiodarone: search for the Holy Grail. Europace 11: 402-404 [Full Text]  
• Doyle, J. F., Ho, K. M. (2009). Benefits and Risks of Long-term Amiodarone Therapy for Persistent Atrial Fibrillation: A Meta-analysis. Mayo Clin Proc. 84: 234-242 [Abstract] [Full Text]  
• Geller, J. C., Egstrup, K., Kulakowski, P., Rosenqvist, M., Jansson, M. A., Berggren, A., Edvardsson, N., Sager, P., Crijns, H. J. (2009). Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009. J Clin Pharmacol 49: 312-322 [Abstract] [Full Text]  
• Friedlander, A. H., Yoshikawa, T. T., Chang, D. S., Feliciano, Z., Scully, C. (2009). Atrial Fibrillation: Pathogenesis, Medical-Surgical Management and Dental Implications. Journal of the American Dental Association 140: 167-177 [Abstract] [Full Text]  
• Malmborg, H., Lonnerholm, S., Blomstrom-Lundqvist, C. (2008). Acute and clinical effects of cryoballoon pulmonary vein isolation in patients with symptomatic paroxysmal and persistent atrial fibrillation. Europace 10: 1277-1280 [Abstract] [Full Text]  
• Hauser, T. H., Peters, D. C., Wylie, J. V., Manning, W. J. (2008). Evaluating the left atrium by magnetic resonance imaging. Europace 10: iii22-iii27 [Abstract] [Full Text]  
• Ahmed, S., Rienstra, M., Crijns, H. J. G. M., Links, T. P., Wiesfeld, A. C. P., Hillege, H. L., Bosker, H. A., Lok, D. J. A., Van Veldhuisen, D. J., Van Gelder, I. C., for the CONVERT Investigators, (2008). Continuous vs Episodic Prophylactic Treatment With Amiodarone for the Prevention of Atrial Fibrillation: A Randomized Trial. JAMA 300: 1784-1792 [Abstract] [Full Text]  
• Blaauw, Y, Crijns, H J G M (2008). Treatment of atrial fibrillation. Heart 94: 1342-1349 [Full Text]  
• Camm, A. J., Reiffel, J. A. (2008). Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl 10: H55-H78 [Abstract] [Full Text]  
• Haywood, G., Nuta, B. (2008). Getting the BEST out of DCCV. Heart 94: 830-831 [Full Text]  
• Morguet, A. J, Kuhnelt, P., Kallel, A., Rauch, U., Schultheiss, H.-P. (2008). Utilization of telemedicine by heart disease patients following hospitalization. J Telemed Telecare 14: 178-181 [Abstract] [Full Text]  
• Savelieva, I., Camm, J. (2008). Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10: 647-665 [Abstract] [Full Text]  
• Noheria, A., Kumar, A., Wylie, J. V. Jr, Josephson, M. E. (2008). Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation: A Systematic Review. Arch Intern Med 168: 581-586 [Abstract] [Full Text]  
• Cosio, F. G., Aliot, E., Botto, G. L., Heidbuchel, H., Geller, C. J., Kirchhof, P., De Haro, J.-C., Frank, R., Villacastin, J. P., Vijgen, J., Crijns, H. (2008). Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace 10: 21-27 [Abstract] [Full Text]  
• Marine, J. E. (2007). Catheter Ablation Therapy for Supraventricular Arrhythmias. JAMA 298: 2768-2778 [Abstract] [Full Text]  
• Kapoor, J. R. (2007). Use of Amiodarone. JAMA 298: 2617-2617 [Full Text]  
• Vassallo, P., Trohman, R. G. (2007). Use of Amiodarone Reply. JAMA 298: 2618-2618 [Full Text]  
• Arlet, J.-B., Chouchana, L., Capron, L., Fink, A. H. Jr., Singh, B. N., Hohnloser, S. H., Ezekowitz, M. D. (2007). Dronedarone in Atrial Fibrillation. NEJM 357: 2403-2405 [Full Text]  
• Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 28: 2803-2817 [Abstract] [Full Text]  
• Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H.-C., Goette, A., Hindricks, G., Hohnloser, S., Kappenberger, L., Kuck, K.-H., Lip, G. Y.H., Olsson, B., Meinertz, T., Priori, S., Ravens, U., Steinbeck, G., Svernhage, E., Tijssen, J., Vincent, A., Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace 9: 1006-1023 [Abstract] [Full Text]  
• Vassallo, P., Trohman, R. G. (2007). Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications. JAMA 298: 1312-1322 [Abstract] [Full Text]  
• Singh, B. N., Connolly, S. J., Crijns, H. J.G.M., Roy, D., Kowey, P. R., Capucci, A., Radzik, D., Aliot, E. M., Hohnloser, S. H., the EURIDIS and ADONIS Investigators, (2007). Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter. NEJM 357: 987-999 [Abstract] [Full Text]  
• Ezekowitz, M. D. (2007). Maintaining Sinus Rhythm -- Making Treatment Better Than the Disease. NEJM 357: 1039-1041 [Full Text]  
• Singh, B. N., Aliot, E. (2007). Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity?. Eur Heart J Suppl 9: G17-G25 [Abstract] [Full Text]  
• Jais, P., Packer, D. L. (2007). Ablation vs. drug use for atrial fibrillation. Eur Heart J Suppl 9: G26-G34 [Abstract] [Full Text]  
• Essebag, V., Reynolds, M. R., Hadjis, T., Lemery, R., Olshansky, B., Buxton, A. E., Josephson, M. E., Zimetbaum, P. (2007). Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. Arch Intern Med 167: 1648-1653 [Abstract] [Full Text]  
• Rehman, H. u., Kurnik, D., Loebstein, R., Olchovsky, D., Coceani, M., Skolnik, N., Armon, C., Zimetbaum, P. (2007). Amiodarone for Atrial Fibrillation. NEJM 356: 2424-2426 [Full Text]  
• Clarke, M., Hopewell, S., Chalmers, I. (2007). Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. JRSM 100: 187-190 [Abstract] [Full Text]  
• Rivard, L., Sinno, H., Shiroshita-Takeshita, A., Schram, G., Leung, T.-K., Nattel, S. (2007). The pharmacological response of ischemia-related atrial fibrillation in dogs: Evidence for substrate-specific efficacy. Cardiovasc Res 74: 104-113 [Abstract] [Full Text]  
• Zimetbaum, P. (2007). Amiodarone for Atrial Fibrillation. NEJM 356: 935-941 [Full Text]  
• Sulke, N, Sayers, F, Lip, G Y H, on behalf of the Guideline Development Group for t, (2007). Rhythm control and cardioversion. Heart 93: 29-34 [Full Text]  
• Waldhauser, K. M., Torok, M., Ha, H.-R., Thomet, U., Konrad, D., Brecht, K., Follath, F., Krahenbuhl, S. (2006). Hepatocellular Toxicity and Pharmacological Effect of Amiodarone and Amiodarone Derivatives. J. Pharmacol. Exp. Ther. 319: 1413-1423 [Abstract] [Full Text]  
• Van Gelder, I. C., Hemels, M. E.W. (2006). The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 8: 943-949 [Abstract] [Full Text]  
• Wyse, D. G. (2006). Transvenous Radiofrequency Catheter Ablation for Atrial Flutter and Atrial Fibrillation: The End of the Beginning?. Circulation 114: 1670-1672 [Full Text]  
• Hall, W. J. (2006). Update in geriatrics.. ANN INTERN MED 145: 538-543 [Full Text]  
• Hemels, M. E.W., Van Noord, T., Crijns, H. J.G.M., Van Veldhuisen, D. J., Veeger, N. J.G.M., Bosker, H. A., Wiesfeld, A. C.P., Van den Berg, M. P., Ranchor, A. V., Van Gelder, I. C. (2006). Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion for the Improvement of Rhythm Control for Persistent Atrial Fibrillation. J Am Coll Cardiol 48: 1001-1009 [Abstract] [Full Text]  
• Lombardi, F., Borggrefe, M., Ruzyllo, W., Luderitz, B., for the A-COMET-II Investigators, (2006). Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J 27: 2224-2231 [Abstract] [Full Text]  
• Writing Committee Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 8: 651-745 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: 854-906 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society . J Am Coll Cardiol 48: e149-e246 [Full Text]  
• Falk, R. H. (2006). Atrial Fibrillation or Sinus Rhythm?: Controversy and Contradiction in Quality of Life Outcomes. J Am Coll Cardiol 48: 731-733 [Full Text]  
• Singh, S. N., Tang, X. C., Singh, B. N., Dorian, P., Reda, D. J., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., Lewis, H. D. Jr, Lopez, B., Raisch, D. W., Ezekowitz, M. D., for the SAFE-T Investigators, (2006). Quality of Life and Exercise Performance in Patients in Sinus Rhythm Versus Persistent Atrial Fibrillation: A Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol 48: 721-730 [Abstract] [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354 [Full Text]  
• Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ACC/AHA TASK FORCE MEMBERS, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B., ESC COMMITTEE FOR PRACTICE GUIDELINES, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L. (2006). ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation--Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: 700-752 [Full Text]  
• Authors/Task Force Members, , Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., Olsson, S. B., Prystowsky, E. N., Tamargo, J. L., Wann, S., ESC Committee for Practice Guidelines, , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, A. J., Dean, V., Deckers, J. W., Despres, C., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J. L., Zamorano, J. L., ACC/AHA (Practice Guidelines) Task Force Members, , Smith, S. C. Jr, Jacobs, A. K., Adams, C. D., Anderson, J. L., Antman, E. M., Halperin, J. L., Hunt, S. A., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 27: 1979-2030 [Full Text]  
• Hu, C L, Jiang, H, Tang, Q Z, Zhang, Q H, Chen, J B, Huang, C X, Li, G S (2006). Comparison of rate control and rhythm control in patients with atrial fibrillation after percutaneous mitral balloon valvotomy: a randomised controlled study. Heart 92: 1096-1101 [Abstract] [Full Text]  
• Jolobe, O. (2006). Inadvertent toxic drug reaction in the management of atrial fibrillation.. JRSM 99: 220-220 [Full Text]  
• Lafuente-Lafuente, C., Mouly, S., Longas-Tejero, M. A., Mahe, I., Bergmann, J.-F. (2006). Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials.. Arch Intern Med 166: 719-728 [Abstract] [Full Text]  
• Scheinman, M. M., Keung, E. (2006). The Year in Clinical Electrophysiology. J Am Coll Cardiol 47: 1207-1213 [Full Text]  
• Leaver, S. K, Ho, T. B L (2006). Inadvertent toxic drug reaction in the management of atrial fibrillation.. JRSM 99: 149-150 [Full Text]  
• George Wyse, D (2006). Pulmonary vein isolation was better than antiarrhythmic drugs for symptomatic atrial fibrillation. Evid. Based Med. 11: 16-16 [Full Text]  
• Gerstenfeld, E. P. (2005). Does Rhythm Control Improve Functional Status in Patients With Atrial Fibrillation?. J Am Coll Cardiol 46: 1900-1901 [Full Text]  
• Futterman, L. G., Lemberg, L. (2005). Atrial Fibrillation. Am J Crit Care 14: 438-440 [Full Text]  
• Rubinstein, J., Zimetbaum, P. J., Josephson, M. E., Schlegel, A., Desai, K. R., Singh, B. N., Singh, S. N., Reda, D. (2005). Amiodarone versus sotalol for atrial fibrillation.. NEJM 353: 627-630 [Full Text]  
• Wadhani, N., Singh, B. N. (2005). Prolongation of Repolarization as Antifibrillatory Action Revisited: Drug Combination Therapy in Atrial Fibrillation. J CARDIOVASC PHARMACOL THER 10: 149-152  
• Malik, I. (2005). JournalScan. Heart 91: 991-992 [Full Text]  
• Zimetbaum, P. (2005). An Argument for Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Circulation 111: 3150-3156 [Full Text]  
• (2005). Amiodarone vs. Sotalol for Persistent AFib. Journal Watch Cardiology 2005: 2-2 [Full Text]  
• Singh, B. N. (2005). Atrial Fibrillation: The Rate or Rhythm Controversy Can It be Resolved on the Basis of Clinical Trial Data?. J CARDIOVASC PHARMACOL THER 10: 81-83